

Optimizing COVID-19 control with asymptomatic surveillance testing in a university environment

Cara E. Brook^{1,2*}, Graham R. Northrup³, Alexander J. Ehrenberg^{1,4,5,6}, the IGI SARS-CoV-2 Testing Consortium⁴, Jennifer A. Doudna^{4,7,8,9,10}, and Mike Boots^{1,11}

¹ Department of Integrative Biology, University of California, Berkeley

² Department of Ecology and Evolution, University of Chicago

³ Center for Computational Biology, College of Engineering, University of California, Berkeley

⁴ Innovative Genomics Institute, University of California, Berkeley

⁵ Helen Wills Neuroscience Institute, University of California, Berkeley

⁶ Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco

⁷ Department of Molecular and Cell Biology, University of California, Berkeley

⁸ College of Chemistry, University of California, Berkeley

⁹ J. David Gladstone Institutes, San Francisco, CA

¹⁰ Howard Hughes Medical Institute, University of California, Berkeley

¹¹ Department of Biosciences, University of Exeter, Penryn, UK

*corresponding author: *Cara E. Brook*

address: 1101 East 57th Street, Chicago, IL, 60637

phone: 707-241-5550

email: cbrook@uchicago.edu

1 **Abstract:**

2 The high proportion of transmission events derived from asymptomatic or presymptomatic
3 infections make SARS-CoV-2, the causative agent in COVID-19, difficult to control through the
4 traditional non-pharmaceutical interventions (NPIs) of symptom-based isolation and contact
5 tracing. As a consequence, many US universities developed asymptomatic surveillance testing
6 labs, to augment NPIs and control outbreaks on campus throughout the 2020-2021 academic year
7 (AY); several of those labs continue to support asymptomatic surveillance efforts on campus in
8 AY2021-2022. At the height of the pandemic, we built a stochastic branching process model of
9 COVID-19 dynamics at UC Berkeley to advise optimal control strategies in a university
10 environment. Our model combines behavioral interventions in the form of group size limits to
11 deter superspreading, symptom-based isolation, and contact tracing, with asymptomatic
12 surveillance testing. We found that behavioral interventions offer a cost-effective means of
13 epidemic control: group size limits of six or fewer greatly reduce superspreading, and rapid
14 isolation of symptomatic infections can halt rising epidemics, depending on the frequency of
15 asymptomatic transmission in the population. Surveillance testing can overcome uncertainty
16 surrounding asymptomatic infections, with the most effective approaches prioritizing frequent
17 testing with rapid turnaround time to isolation over test sensitivity. Importantly, contact tracing
18 amplifies population-level impacts of all infection isolations, making even delayed interventions
19 effective. Combination of behavior-based NPIs and asymptomatic surveillance also reduces
20 variation in daily case counts to produce more predictable epidemics. Furthermore, targeted,
21 intensive testing of a minority of high transmission risk individuals can effectively control the
22 COVID-19 epidemic for the surrounding population. Even in some highly vaccinated university
23 settings in AY2021-2022, asymptomatic surveillance testing offers an effective means of
24 identifying breakthrough infections, halting onward transmission, and reducing total caseload.
25 We offer this blueprint and easy-to-implement modeling tool to other academic or professional
26 communities navigating optimal return-to-work strategies.

27

28

29 **Keywords:** COVID-19; asymptomatic surveillance testing; branching process model; university
30 control

31

32

33

34

35

36

37

38

39

40

41

42 **Introduction**

43 Non-pharmaceutical interventions (NPIs) to control the spread of infectious diseases vary
44 in efficacy depending on the natural history of pathogen that is targeted [1]. Highly transmissible
45 pathogens and pathogens for which the majority of onward transmission events take place prior
46 to the onset of symptoms are notoriously difficult to control with standard public health
47 approaches, such as isolation of symptomatic individuals and contact tracing [1]. SARS-CoV-2,
48 the causative agent in COVID-19, is a clear example of one of these difficult-to-control
49 pathogens [2]. While the first SARS-CoV was effectively contained via the isolation of
50 symptomatic individuals following emergence in 2002 [3], at the time of this article's revision,
51 SARS-CoV-2 remains an ongoing public health menace that has infected more than 240 million
52 people worldwide [4]. Though the two coronaviruses are epidemiologically comparable in their
53 original basic reproduction numbers (R_0) [3], SARS-CoV-2 has evaded control efforts largely
54 because the majority of virus transmission events occur prior to the onset of clinical symptoms in
55 infected persons [2]—in stark contrast to infections with the first SARS-CoV [3]. Indeed, in
56 many cases, SARS-CoV-2-infected individuals never experience symptoms at all [5–8] but,
57 nonetheless, remain capable of transmitting the infection to others [9–13]. Due to the challenges
58 associated with asymptomatic and presymptomatic transmission [10], surveillance testing of
59 asymptomatic individuals has played an important role in COVID-19 epidemic control [14–16].
60 Asymptomatic surveillance testing is always valuable for research purposes, but its efficacy as a
61 public health intervention will depend on both the epidemiology of the focal infection and the
62 characteristics of the testing regime. Here, we explore the effects of both behavior-based NPIs
63 and asymptomatic surveillance testing on COVID-19 control in a university environment.

64 In year two of the COVID-19 pandemic, the United States still leads the globe with over
65 46 million reported cases of COVID-19 [4], and universities across the nation continue to
66 struggle to control epidemics in their campus communities [17]. To combat this challenge in
67 AY2020-2021, colleges adopted a variety of largely independent COVID-19 control tactics,
68 ranging from entirely virtual formats to a mix of in-person and remote learning, paired with strict
69 behavioral regulations, and—in some cases—in-house asymptomatic surveillance testing [18]. In
70 AY2021-2022, asymptomatic surveillance testing continues to play a key role in expanded plans
71 for university reopening [18,19], even on some campuses which also mandate vaccination [20].
72 In March 2020, shortly after the World Health Organization declared COVID-19 to be a global
73 pandemic [21], the University of California, Berkeley, launched its own pop-up SARS-CoV-2
74 testing lab in the Innovative Genomics Institute (IGI) [22] with the aim of providing COVID
75 diagnostic services to the UC Berkeley community and underserved populations in the
76 surrounding East Bay region. Though the IGI RT-qPCR-based pipeline was initially developed
77 to service clinical, symptomatic nasopharyngeal and oropharyngeal swab samples [22], the IGI
78 subsequently inaugurated an asymptomatic surveillance testing program for the UC Berkeley
79 community [23], through which—at the time of this revision—over 60,000 faculty, students, and
80 staff in the UC Berkeley community have since been serviced with over 440,000 tests and

81 counting [24]. From June 2020-May 2021, weekly asymptomatic surveillance testing was
82 mandatory for any UC Berkeley community member working on campus; testing requirements
83 were relaxed in May 2021 for those providing proof of vaccination.


84 Here we developed a stochastic, agent-based branching process model of COVID-19
85 spread in a university environment to advise UC Berkeley on best-practice approaches for
86 asymptomatic surveillance testing in our community and to offer guidelines for optimal control
87 in university settings more broadly. Previous modeling efforts have used similar approaches to
88 advocate for more frequent testing with more rapid turnaround times at the expense of
89 heightened test sensitivity [14,15] or to weigh the cost-effectiveness of various testing regimes
90 against symptom-based screening in closed university or professional environments [16]. Our
91 model is unique in combining both behavioral interventions with optimal testing design in a real-
92 world setting, offering important insights into efficient mechanisms of epidemic control and an
93 effective tool to optimize control strategies.

94

95 **Materials and methods.**

96 Our model takes the form of a stochastic branching process model, in which a subset
97 population of exposed individuals (0.5%, derived from the mean percentage of positive tests in
98 our UC Berkeley community [24]) is introduced into a hypothetical 20,000 person community
99 that approximates our university campus utilization goals from spring 2021. With each timestep,
100 the disease parameters for each infected case are drawn stochastically from distributions
101 representing the natural history of the SARS-CoV-2 virus, paired with realistic estimates of the
102 timeline of corresponding public health interventions [2,16,25] (Fig. 1). Our flexible model (Text
103 S1; published here with open-access R-code [26]) allows for the introduction of NPIs for
104 COVID-19 control in four different forms: (1) group size limits, (2) symptom-based isolations,
105 (3) asymptomatic surveillance testing isolations, and (4) contact tracing isolations that follow
106 after cases are identified through screening from symptomatic or asymptomatic surveillance
107 testing (Table 1). Because we focused our efforts on optimal asymptomatic surveillance testing
108 regimes, we did not explicitly model other NPIs, such as social distancing and mask wearing;
109 however, the effects of these behaviors were captured in our representation of $R_{\text{effective}}$
110 (hereafter, R_E) for both within-campus and out-of-campus transmission. Since vaccination
111 against SARS-CoV-2 became widely available during the review process of our article
112 (including a vaccine mandate across the University of California school system [27]), we
113 updated our original model to allow for flexible starting conditions that include a variable
114 proportion of vaccinated individuals in a specific university setting. We allowed a randomly
115 selected 5% of vaccinated individuals to become infected and infectious as “breakthrough cases”
116 (consistent with published estimates of vaccine efficacy for the Pfizer-BioNTech mRNA vaccine
117 with the most widespread uptake in the US [28]). For simplicity, we assumed that all infectious
118 individuals were equally transmissible, regardless of vaccination status (though see ‘Discussion’
119 for future research objectives). After experiencing infection, we further assumed that all
120 individuals became recovered and immune for the remaining duration of our simulations, as our

121 focal timescale of interest (the academic semester) is shorter than most projections of the
 122 duration of immunity to SARS-CoV-2 [29,30].



123
 124 **Fig. 1: Conceptual schematic of branching process model of SARS-CoV-2 dynamics.**
 125 Person A is isolated through testing after exposing Person B and Person C. Person B is then isolated through contact
 126 tracing, while Person C is not traced but is nonetheless ultimately isolated through symptomatic surveillance. A viral
 127 titer trajectory (right) is derived from a within-host viral kinetics model (Text S2)—independent trajectories from
 128 20,000 randomly-selected individuals are shown here to highlight the range of possible variation. The 25th and 75th
 129 titer threshold percentile for the onset of symptoms are depicted in pink, such that 32% of individuals modeled in
 130 our simulations did not present symptoms. Schematic is adapted in concept from Hellewell et al. (2020) [31].
 131

132 **Table 1: Parameter ranges and interventions included in model.**

Parameter	Values investigated	References*
Basic epidemiology		
Population size	• 20,000	---
Number initially infected	• 100	---
Possible cases per infectious individual (R_0), prior to environmental corrections	<ul style="list-style-type: none"> • Negative binomial distribution (main text): mean = 2.5; $k = 0.10$ • Lognormal distribution (Fig. S2): mean=2.5; sd = 0.10 • Negative binomial distribution, Delta (Fig. S7, S8): mean = 2.5; $k = 0.10$. 	[32,33]
Transmission events per infectious individual	• Poisson distribution: $\lambda = 3$	---
Virus generation time	• Weibull distribution: $k = 2.826$; $\lambda = 5.665$	[2]
Proportion of transmissions maintained within the UCB community	<ul style="list-style-type: none"> • 90% (main text) • 50% (Fig. S5) 	---
Population proportion vaccinated	<ul style="list-style-type: none"> • 0% (main text) • 97.7% (Fig. S7) • 60% (Fig. S8) 	[24,34]
Proportion of vaccinated individuals experiencing breakthrough cases	<ul style="list-style-type: none"> • 0% (main text) • 5% (Fig. S7, S8) 	[28]
Threshold viral titer for symptom onset	• Lognormal distribution: mean = 10^5 viral cp/μl RNA; sd = 10^4 viral cp/μ (main text; yields ~30% asymptomatic infections)	[6,7]

- Lognormal distribution: mean = 10^7 viral cp/ μ l RNA; sd = 10^4 viral cp/ μ l (Fig. S3; yields ~50% asymptomatic infections)

Behaviour-based NPIs		
Group size limits	• 6, 12, 16, 20, 50, no limit (main text; Fig. S1, S2)	---
Population proportion adhering to group size limits	• 90% (main text; Fig. S2) • 50% (Fig. S1)	---
Lag time to symptomatic isolation	• Normal distribution: mean = 1,2,3,4,5 days; sd = .5 days	---
Lag time to contact tracing	• Normal distribution: mean = 1 day; sd = .5 days	---
Population proportion participating in contact tracing	• 0% (main text) • 90% (Fig. S4)	---
Testing interventions		
Testing frequency	• semi-weekly (2x/week) • weekly • every-two-weeks	---
Test days per week	• 2 (main text) • 5, 7 (Fig. S6)	---
Testing turnaround time	• Normal distribution: mean = 1,2,3,4,5,10 days; sd=.5 days	---
Test limit of detection	• 10^1 , 10^3 , 10^5 viral cp/ μ l RNA	[22,35–39]

**if applicable; otherwise, indicates a parameter investigated in this analysis.*

133
 134 R_E is the product of the pathogen basic reproduction number (R_0) and the proportion of
 135 the population that is susceptible to disease. R_E is thus a dynamic value which corresponds to the
 136 number of new infections caused by a single infection at a given timepoint within a specified
 137 community. We computed an independent R_E for each infectious person in our population as a
 138 combined result of both heterogeneity in individual infectiousness and heterogeneity in
 139 individual contact events that could result in transmission. To determine R_E , we first drew a
 140 value of potential cases for each infectious individual from the SARS-CoV-2 negative binomial
 141 distribution for R_0 , estimated to have a mean value of 2.5 and a dispersion parameter (k) of 0.10
 142 [32]; in later analyses incorporating highly vaccinated university settings reflective of the reality
 143 of AY2021-2022, we shifted the mean to a value of 6 to better approximate the dynamics of
 144 highly transmissible variants of concern (e.g. the Delta variant) [33]. Though representation of
 145 R_E in log-normal vs. negative binomial form will not change the average number of cases
 146 generated per epidemic, the negative binomial distribution replicates the dynamics of
 147 superspreading events, which are known to play an important role in SARS-CoV-2 dynamics
 148 [40–45]. Indeed, there is strong direct empirical evidence that COVID-19 epidemiology exhibits
 149 a negative binomial R_E across multiple systems [44,46–48]; as few as 10% of infectious
 150 individuals may be responsible for 80% of onward SARS-CoV-2 transmissions [49].

151 After drawing potential cases for each infectious individual, we next hypothesized that
 152 most university students would interact predominantly with other students vs. people from the
 153 surrounding community and, thus, modeled only a minority (10%) of possible onward
 154 transmissions as lost to the external community (e.g. an infectious UC Berkeley community

155 member infects someone outside the UC Berkeley community), though see ‘Results’ for
156 discussion of sensitivity analysis of this assumption.

157 Next, we assumed that social distancing, masking, and behavioral modifications in our
158 community would modulate dynamics such that some of the remaining 90% (or 50% in
159 sensitivity analyses) of the original R_0 -derived potential infections do not take place. Because we
160 were specifically interested in advising UC Berkeley on group size limits for gatherings, we then
161 drew a number of possible onward transmission events for each infectious individual from a
162 simple Poisson distribution with $\lambda = 3$, signifying the average number of possible encounters
163 (i.e. cross-household dining, shared car rides, indoor meetings, etc.) per person that could result
164 in transmission. We then use published estimates of the generation time of onward transmission
165 events for SARS-CoV-2 infection [2] to draw event times for these encounters and distributed
166 each infectious person’s original number of R_0 -derived potential cases among these events at
167 random. This ensured that multiple transmissions were possible at a single event; the most
168 extreme superspreading events occur when persons with heterogeneously high infectiousness
169 draw a large number of potential cases, which are concentrated within a relatively small number
170 of discrete transmission events. When we imposed group size limit NPIs in our model, we
171 truncated case numbers for each event at the intervention limit.

172 For each infectious individual, we additionally generated an independent virus trajectory,
173 using a within-host viral kinetics model for SARS-CoV-2 upper respiratory tract infections,
174 structured after the classic target cell model [50–53] (Text S2). From each independent virus
175 trajectory, we inferred a time-varying transmissibility, modeled as a Michaelis-Menten-like
176 function of viral load [53]. We fixed the within-host viral kinetics model constant, θ , at a value
177 that allowed for a ~50% probability of infection occurring per transmissible contact event at an
178 infectious individual’s peak viral load [53]. Because all possible onward transmissions were
179 assigned an event generation time, we next evaluated the viral load of the infectious person at the
180 time of each potential transmission to determine whether or not it actually occurred. By these
181 metrics, our original R_0 -derived possible cases were halved, such that R_E , the number of average
182 onward infections caused by a single infectious person in the UC Berkeley community, was
183 reduced to just over one ($R_E=1.05$), or just under three ($R_E=2.94$) in the case of Delta variant
184 simulations, consistent with published estimates of Bay Area R_E and initial asymptomatic test
185 results in our community from the first year of the pandemic [24,54]. The majority of modelled
186 transmission events occurred when the infectious host had higher viral titers, thus biasing new
187 case generations towards earlier timesteps in an individual’s infection trajectory, often occurring
188 prior to the onset of symptoms as is realistic for COVID-19 [25] (Fig. 1).

189 In addition to modulating the probability of onward transmission events, each infectious
190 individual’s virus trajectory additionally allowed us to compute a timing of symptom onset,
191 which corresponded to the timepoint at which an individual’s virus trajectory crossed some
192 threshold value for presentation of symptoms. We drew each threshold randomly from a log-
193 normal distribution with a mean of 10^5 virus copies per μl of RNA; by these metrics, roughly
194 32% of our modeled population presented as asymptomatic, in keeping with published estimates

195 for SARS-CoV-2 [6,7]. Using each infectious individual’s viral load trajectory, we were next
196 able to compute a period of test sensitivity, corresponding to the time during which viral load is
197 high enough for detection by the virus test in question, based on the modeled limit of detection.
198 Asymptomatic surveillance testing results in higher “false-negative” test results both very early
199 and very late in infection when viral loads are below the detection limit for the adopted assay
200 [55] (Fig. 1), though most tests should reliably detect infectious cases with viral titers $>10^6$ cp/ μ l
201 [56–58]. We explored dynamics across a range of published values for test limits of detection:
202 10^1 , 10^3 , and 10^5 virus copies per μ l of RNA. The IGI’s RT-qPCR-based testing pipeline has a
203 published sensitivity of 1 cp/ μ l [22], while the majority of SARS-CoV-2 RT-qPCR tests
204 nationally are reliable above a 10^3 cp/ μ l threshold [35]; less-sensitive antigen-based and LAMP
205 assays report detection limits around 10^5 cp/ μ l [36,37]. Some commercially-available COVID-19
206 test kits detection limits in TCID₅₀/ml, which corresponds to the median tissue culture infectious
207 dose, roughly approximating a threshold for the infectious viral load. Though exact values will
208 vary depending on the virus, cell type, and assay conditions, a 100 TCID₅₀/ml limit of detection
209 for SARS-CoV-2 has been shown to correspond to a viral load detection limit between 10^2 and
210 10^3 cp/ μ l RNA [38,39]. For reference, the Abbot BinaxNOW™ COVID-19 Ag card reports a
211 limit of detection of 140.6 TCID₅₀/ml (between 10^2 and 10^3 cp/ μ l RNA), while the QuickVue At-
212 Home COVID-19 test reports a limit of detection of 1.91×10^4 TCID₅₀/ml (between 10^4 and 10^5
213 cp/ μ l RNA).

214 In addition to within-community transmissions, all individuals in the modeled population
215 were also subjected to a daily hazard (0.25% in standard model runs and 0.60% in Delta variant
216 runs) of becoming infected from an external source, based on published estimates of R_E and
217 COVID-19 prevalence in Alameda County [54,59]. We report the mean results of 100 stochastic
218 runs of each proposed intervention.

219


220 **Results.**

221 **Comparing behavioral NPIs for COVID-19 control.**

222 We first ran a series of epidemic simulations using a completely mixed population of
223 20,000 individuals subject to the infection dynamics outlined above to compare and contrast the
224 impacts of our four NPIs on COVID-19 control. We introduced an initial population of 100
225 infectious individuals (0.5%) at timestep 0 and compared the effects of a single intervention on
226 epidemic trajectories after the first 50 days of simulation. Less intensive or intervention-absent
227 scenarios allowed infectious cases to grow at unimpeded exponential rates, rapidly exhausting
228 our susceptible supply and making it necessary to compare results at a consistent (and early)
229 timepoint in our simulated epidemics.

230 As a consequence of our representation of R_E in negative binomial form, we first
231 considered the COVID-19 control effectiveness of group size limits on in-person gatherings,
232 which doubled as upper thresholds in transmission capacity (Fig. 2). Assuming that 90% of the
233 modeled population adhered to assumed group size regulations, we found that limiting outdoor
234 gatherings to groups of six or fewer individuals saved a mean of $\sim 7,900$ cases per 50-day

235 simulation (in a 20,000 person population) and corresponded to an R_E reduction of nearly 0.20
 236 (reducing R_E from 1.05 to subclinical 0.86; Fig. 2; Dataset S1). By contrast, a large group size
 237 limit of 50 persons had almost no effect on epidemic dynamics; under published estimates of
 238 SARS-CoV-2 negative binomial R_E [32], a group size limit of 50 will restrict transmission from
 239 only 0.00039% of infectious individuals (Fig. 2). Intriguingly, in sensitivity analyses exploring
 240 assumptions of only 50% adherence to group size limits, we witnessed larger caseloads only at
 241 group size limits of 16 or fewer individuals (Fig. S1); at group sizes of 20 or more individuals,
 242 density limits were so ineffective already that reducing adherence had no power to further
 243 undermine the intervention’s impacts. Gains in epidemic control from group size limits resulted
 244 from avoidance of superspreading events, an approach that was effective for negative binomial
 245 but not log-normal representations of R_E that lack the transmission “tail” characteristic of a
 246 superspreader distribution [45] (Fig. S2). Importantly, by avoiding superspreading events, group
 247 size limits also reduced variance in daily case counts, yielding more predictable epidemics,
 248 which are easier to control through testing and contact tracing [2,25,31]. Over the July 4, 2020
 249 weekend, asymptomatic surveillance testing resources in our UC Berkeley community were
 250 overwhelmed and containment efforts challenged after a single superspreading event on campus
 251 [60].



252
 253 **Fig. 2: Effects of group size limits on COVID-19 dynamics.**


254 **A.** Negative binomial R_E distribution with mean = 1.05 and dispersion parameter (k) = 0.10. The colored vertical
 255 dashes indicate group size limits that ‘chop the tail’ on the R_E distribution; for 90% of the population, coincident
 256 cases allocated to the same transmission event were truncated at the corresponding threshold for each intervention.

257 **B.** Daily new cases and, **C.** Cumulative cases, across a 50-day time series with 95% confidence intervals by standard
 258 error depicted under corresponding, color-coded group size limits.

259

260 We next investigated the impacts of variation in lag time to self-isolation post-symptom
 261 onset for the just under 70% of individuals likely to present with COVID-19 symptoms in our
 262 modeled population (Fig. 3). At UC Berkeley, all essential students, faculty, and staff must
 263 complete a digital ‘Daily Symptom Screener’ before being cleared to work on campus; here, we
 264 effectively modeled the delay post-initial symptom onset to the time at which each individual
 265 recognizes symptoms sufficiently to report to the Screener and isolate. For each infected
 266 individual in our population, we drew a symptom-based isolation lag from a log-normal

267 distribution centered on a mean of one to five days, assuming the entire population to be
 268 compliant with the selected lag.



269
 270 **Fig. 3: Impacts of NPIs on COVID-19 control.**
 271 **A.** Mean reduction in R_E^* and **B.** cumulative cases saved across 50-day simulated epidemics under assumptions of
 272 differing non-pharmacological interventions (NPIs). NPIs are color-coded by threshold number of persons for
 273 group-size limits, lag-time for symptom-based isolations, and mean turnaround time from test positivity to isolation
 274 of infectious individuals for testing isolations. For testing isolations, shading hue corresponds to test limit of
 275 detection with the darkest colors indicating the most sensitive tests with a limit of detection of 10^1 virus copies/ μ l of
 276 RNA. Progressively lighter shading corresponds to limits of detection = 10^3 , 10^5 , and 10^7 cp/ μ l.
 277 *Note: R_E reduction (panel A) is calculated as the difference in mean R_E in the absence vs. presence of a given NPI.
 278 The upper confidence limit (uci) in R_E reduction is calculated as the difference in uci R_E in the absence vs. presence
 279 of NPI. In our model, mean R_E in the absence of NPI equals 1.05 and uci R_E in the absence of NPI equals 8.6.
 280

281 By these metrics, a rapid, one day lag in symptom-based isolation was the fourth-most
 282 effective intervention in our study, with a mean of more than 13,100 cases saved in a 50-day
 283 simulation (again, in a 20,000 person population), corresponding to an R_E reduction of 0.67,
 284 from 1 to 0.38 (Dataset S1). Longer lag times to isolation produced less dramatic results, but
 285 even an average five-day lag to isolation post-symptom onset nonetheless yielded more than
 286 4,000 cases saved and reduced R_E by a mean of 0.06. The efficacy of symptom-based isolation
 287 decreased at higher virus titer thresholds for symptom onset, corresponding to a higher
 288 asymptomatic proportion ($\sim 50\%$) of the population (Fig. S3); some empirical findings suggest
 289 that these higher titer thresholds for symptom onset may more accurately reflect COVID-19
 290 epidemiology [61]. Because both group size limits and daily screening surveys to facilitate
 291 symptom-based isolation can be implemented without expending substantial resources, we
 292 advocate for these two approaches as particularly cost-effective COVID-19 control strategies for
 293 all university and small community environments—especially those lacking an on-site
 294 asymptomatic surveillance testing lab.
 295

296 **Comparing asymptomatic surveillance testing for COVID-19 control.**

297 Our primary motivation in developing this model was to advise UC Berkeley on best-
298 practices for asymptomatic surveillance testing. As such, we focused efforts on determining the
299 most effective use of testing resources by comparing asymptomatic surveillance testing across a
300 range of approaches that varied test frequency, test turnaround time (the time from which the test
301 was administered to the timing of positive case isolation), and test sensitivity (based on the limit
302 of detection).

303 We compared all permutations of asymptomatic surveillance testing, varying test
304 frequency across semi-weekly, weekly, and every-two-week regimes, investigating turnaround
305 time across delays of one to five and ten days, and exploring limits of detection of 10^1 , 10^3 , and
306 10^5 virus copies per μl of RNA. These test frequency regimes reflect those considered by UC
307 Berkeley administrators throughout the pandemic: from August-December 2020 and January-
308 April 2021, UC Berkeley undergraduates residing in university residence halls were subject to
309 compulsory semi-weekly asymptomatic surveillance testing, while all other campus community
310 members were permitted to take part in voluntary testing with a recommended weekly or every-
311 two-week frequency. After vaccines became widespread (and eventually mandated), testing
312 requirements for vaccinated undergraduates in residence halls were reduced to once a month.
313 Turnaround time values in our model reflect the reality in range of testing turnaround times from
314 in-house university labs like that at UC Berkeley to institutions forced to outsource testing to
315 commercial suppliers [62], and limits of detection span the range in sensitivity of available
316 SARS-CoV-2 tests [22,35–37].

317 Across testing regimes broadly, we found test frequency, followed by turnaround time, to
318 be the most effective NPIs, with limit of detection exerting substantially less influence on
319 epidemic dynamics, consistent with findings published elsewhere [14,15]. The top three most
320 effective NPIs in our study corresponded to semi-weekly testing regimes with one- and two-day
321 turnaround times across 10^1 and 10^3 cp/ μl limits of detection. These three scenarios yielded
322 mean cases saved ranging from just over 14,000 to just over 13,500 in the first 50 days of
323 simulation and produced an R_E reduction capacity between 0.97 and 0.80 (Fig. 3; Dataset S1).
324 Halving test frequency to a weekly regimen, under assumptions of turnaround time=1 day and
325 limit of detection= 10^1 , resulted in a nearly 48% decrease in the NPI's R_E reduction capacity. By
326 comparison, a single extra day lag from one to two-day turnaround time under semi-weekly
327 testing conditions at limit of detection= 10^1 cp/ μl yielded a modest 16% decrease in R_E reduction
328 capacity. However, longer delays in turnaround time of up to ten days or more—not unusual in
329 the early stages of the COVID-19 pandemic [62]—were not significantly different from
330 scenarios in which no intervention was applied at all. This outcome results from the rapid
331 generation time of SARS-CoV-2 [2]; most infectious individuals will have already completed the
332 majority of subsequent transmissions by the time a testing isolation with a 10-day turnaround
333 time is implemented. Nonetheless, encouragingly, reducing test sensitivity from 10^1 to 10^3 under
334 a semi-weekly, turnaround time=1 day regime decreased R_E reduction capacity by only 18%,
335 offering support to advocates for more frequent but less sensitive tests [63] but also highlighting

336 the added benefit incurred when university testing labs, like that at UC Berkeley, are able to
337 provide both frequent and sensitive PCR-based testing.

338 Addition of a contact tracing intervention, in which 90% of infectious contacts were
339 traced and isolated within a day of the source host isolation, to NPI scenarios already featuring
340 either symptom-based or asymptomatic surveillance testing isolation enhanced each
341 intervention's capacity for epidemic control (Fig. S4). Of note, contact tracing boosted
342 performance of some of the poorest performing testing interventions, such that even those
343 previously ineffective asymptomatic surveillance regimens with 10-day turnaround time
344 nonetheless averted cases and significantly reduced R_E when infectious contacts could be
345 isolated. For a semi-weekly testing regime at limit of detection = 10^1 cp/ μ l and turnaround time
346 = 10 days, the addition of contact tracing increased mean cases saved from ~510 to >8,600 and
347 increased R_E reduction capacity from 0.000080 to 0.27 (Dataset S2).

348

349 **Optimizing combined NPIs for COVID-19 control.**

350 Our modeled simulations suggested that it is possible to achieve largely equivalent gains
351 in COVID-19 control from NPIs in the form of group size limits, symptom-based isolations, and
352 asymptomatic surveillance testing isolations—though gains from symptom-based behavioral
353 isolations were jeopardized under assumptions of a higher proportion of asymptomatic
354 individuals (Fig. S3). Nonetheless, the most effective interventions were realized when
355 behavioral control mechanisms were *combined* with asymptomatic surveillance testing (Fig. 4).
356 Assuming a one day turnaround time and 10^1 cp/ μ l limit of detection, we found that adding (a)
357 contact tracing with 90% adherence and a one-day lag, plus (b) symptom-based isolation with a
358 one-day lag, plus (c) a group size limit of twelve persons to an every-two-week asymptomatic
359 surveillance testing regimen could elevate the R_E reduction capacity from 0.22 to 0.83 and
360 almost double the ~6,600 cases saved from the testing intervention alone (Dataset S3).
361 Combining interventions enabled less rigorous testing regimes to rival the effectiveness of semi-
362 weekly asymptomatic surveillance testing without expending additional resources. In addition,
363 combining interventions resulted in less variation in the cumulative case count, as many layers of
364 opportunity for infection isolation helped limit the likelihood of a superspreading event spiraling
365 out of control. Sensitivity analyses indicated that our findings were largely robust to assumptions
366 of exacerbated insularity in university settings (e.g. when only 1% of transmissions were lost to
367 the outside) but that the impacts of combined interventions were reduced under sensitivity
368 analyses exploring a higher proportion (e.g. 50%) of transmissions lost to the external
369 community (Fig. S5), as interventions can only be applied within the closed campus. These
370 findings highlight the vulnerability of any community public health control measure to disease
371 introductions from beyond the sphere of control. On a macroscale, isolated countries like New
372 Zealand have struggled with this challenge across the course of the COVID-19 pandemic [64].




Fig. 4: Combining behavioral and asymptomatic surveillance testing NPIs for COVID-19 control.

A. Mean reduction in R_{E}^* , **B.** cumulative cases saved, and **C.** daily case counts for the first 50 days of the epidemic, across regimes of differing testing frequency and a combination of asymptomatic surveillance testing, contact tracing, symptomatic isolation, and group size limit interventions. All scenarios depicted here assumed test turnaround time, symptomatic isolation lags, and contact tracing lags drawn from a log-normal distribution with mean=one day. Limit of detection was fixed at 10^1 and group size limits at 12. Dynamics shown here are from simulations in which testing was limited to two test days per week.


*Note: R_E reduction (panel A) is calculated as the difference in mean R_E in the absence vs. presence of a given NPI. The upper confidence limit (uci) in R_E reduction is calculated as the difference in uci R_E in the absence vs. presence of NPI. In our model, mean R_E in the absence of NPI equals 1.05 and uci R_E in the absence of NPI equals 8.6.

Finally, we also experimented with varying the distribution of days allocated to asymptomatic surveillance testing, without changing the frequency with which each individual was tested. Specifically, we explored semi-weekly, weekly, and every-two-week testing regimens in which tests were administered across two, five, and seven available testing days per week. More broadly distributed test days corresponded to fewer tests per day at a population level but, as with more intervention layers, resulted in less variation in the cumulative total cases because testing isolations more closely tracked daily exposures (Fig. S6).

Modeling COVID-19 dynamics in the campus community.

We next sought to advise the IGI on asymptomatic surveillance testing strategies explicitly by simulating epidemics in a more realistic, heterogeneous population modeled after the UC Berkeley campus community in the spring semester of AY2020-2021 (Fig. 5). To this end, we subdivided our 20,000 person university population into a 5,000 person “high transmission risk” cohort and a 15,000 person “low transmission risk” cohort, assuming “high transmission risk” status to correspond to individuals (such as undergraduates), living in high density housing with a majority of contacts (90%) concentrated within the UCB community and

402 “low transmission risk status” to correspond to individuals (such as faculty members or
 403 postdoctoral scholars) with only limited contacts (40%) in the UCB community. We imposed a
 404 12-person group size limit (with 90% adherence) on the population as a whole, as recommended
 405 by the City of Berkeley Public Health Department in the early months of the pandemic [65], and
 406 assumed a one-day average lag in symptom-based isolation for all cohorts. To add additional
 407 realism, we enrolled only 50% of each transmission risk group in our modeled asymptomatic
 408 surveillance testing program (to mimic adherence—though asymptomatic surveillance testing is
 409 compulsory for undergraduates residing in residence halls at UC Berkeley [24]). We assumed
 410 that 95% efficacy in contact tracing (with a mean tracing delay of one day) for those enrolled in
 411 our asymptomatic surveillance program but only 50% efficacy for those not enrolled; UC
 412 Berkeley has encouraged all community members to enroll in the ‘CA Notify’ digital contract
 413 tracing app developed by Apple and Google [66]. For all testing interventions, we assumed limit
 414 of detection= 10^1 cp/ μ l and turnaround time=2 days, the average for the IGI asymptomatic
 415 surveillance testing lab [22].
 416



417
 418 **Fig. 5: Targeted testing of high transmission risk cohorts in a heterogeneous population.**
 419 **A.** Schematic of transmission risk group cohorts in the heterogeneous model. The population is divided into 5,000
 420 “high transmission risk” and 15,000 “low transmission risk” individuals, for which, 90% and 40% of the proportion
 421 of transmission events take place within the UC Berkeley community, respectively. Of those transmission events
 422 within the Berkeley community, the majority (80%) are restricted within the same transmission risk group as the
 423 infector, while 20% are sourced to the opposing risk group. Half of each cohort is assumed to be enrolled in
 424 asymptomatic surveillance testing and subjected to the differing test frequency regimes depicted in panels **B.**
 425 through **D.** Panel **B.** shows the progression of cumulative cases across 730 days of simulation for each testing
 426 regime, while panel **C.** and **D.** give, respectively, the reduction in R_{E}^* and the total cases saved achieved by each test
 427 regime vs. a no intervention baseline.

428 **Note: R_{E} reduction (panel A) is calculated as the difference in mean R_{E} in the absence vs. presence of a given NPI.*
 429 *The upper confidence limit (uci) in R_{E} reduction is calculated as the difference in uci R_{E} in the absence vs. presence*
 430 *of NPI. In our model, mean R_{E} in the absence of NPI equals 1.05 and uci R_{E} in the absence of NPI equals 8.6.*
 431

432

433 We found that targeted, semi-weekly testing of 50% of individuals in the high
434 transmission risk cohort, paired with every-three-week testing of enrolled individuals in the low
435 transmission risk cohort yielded mean R_E reduction and cumulative cases saved on par with that
436 achieved from weekly testing (and better than that achieved from every-two-week testing) of all
437 enrolled individuals in the population at large (Fig. 5). Targeting the highest transmission-risk
438 populations with testing allows practitioners to save valuable resources while simultaneously
439 controlling the epidemic for the entire community. Importantly, while mean R_E reduction and
440 cumulative cases were largely comparable between the targeted, semi-weekly testing regiment
441 and the untargeted, weekly regimen, the observed variance in intervention efficacy (Fig. 5C) was
442 substantially greater for the targeted scenario, in which the low transmission risk cohort was only
443 tested once every three weeks. This results from a higher probability that a rare superspreading
444 event could occur in the infrequently monitored low transmission risk cohort, thus reaffirming
445 our previous observation that more frequent asymptomatic surveillance testing regimens result in
446 more predictable—and easier to control—epidemics.

447 Notably, irrespective of intervention, the diminished transmissibility of the “low
448 transmission risk” population in this heterogeneous model structure greatly reduced epidemic
449 spread in subsequent simulations as compared with those presented previously in the perfectly
450 mixed environment; as a result, we here compared interventions after 500 days of simulation,
451 rather than 50. The heightened realism of our heterogenous population generated slow-moving
452 epidemics more closely resembling those we witnessed in our university environment across
453 AY2020-2021.

454

455 **Modeling vaccinated environments.**

456 During the time in which this article was under review, COVID-19 vaccines became
457 widely available in the US, and the University of California system issued a vaccine mandate for
458 students and staff across all of its campuses, including UC Berkeley [27]. Simultaneously, the
459 highly transmissible Delta variant ($R_0 \sim 6$ [33]) took hold as the most widespread SARS-CoV-2
460 lineage in the United States [67]. To address this new reality, we ran additional simulations of
461 our original, single-population, university testing model, comparing the mosaic of possible
462 interventions exhibited in Fig. 4 under assumptions of $R_0 = 6$ in university settings in which a
463 variable proportion of the student population was vaccinated. Specifically, we compared
464 simulations in a population that was only 60% vaccinated (reflecting the student population of
465 the University of Alabama, Tuscaloosa, a comparably sized public university to UCB but
466 without a vaccine mandate, at the time of writing [34]) to simulations in a population that was
467 97.7% vaccinated (reflecting the UC Berkeley undergraduate population at the time of writing
468 [24]). Over 1,000 US universities and colleges have now issued guidelines mandating
469 vaccination (with some exceptions) for on-campus study [68].

470 In these new simulations, testing, tracing, symptomatic isolation, and group size limit
471 NPIs continued to have scalable impacts on COVID-19 dynamics within each respective

472 university setting (Fig. S7-S8). Baseline R_E under Delta variant assumptions in 60% vaccinated
473 populations without behavior- or testing-based interventions was higher than baseline R_E in
474 unvaccinated populations under standard transmission assumptions (1.12 vs. 1.05). Nonetheless,
475 behavior- and testing-based NPIs easily controlled epidemics in a less susceptible population
476 (Fig. S7). Averted cases were fewer because fewer infections occurred altogether in the partially-
477 vaccinated population. Daily variance in exposure rate narrowed and differences in impact
478 between interventions of variable intensity were less extreme in this more mild epidemic
479 scenario, a pattern even more more pronounced in simulations assuming a 97.7% vaccinated
480 population. Under assumptions of near-complete vaccination and Delta transmission, baseline R_E
481 equaled 0.17, and a testing only intervention with an every-two-week frequency was sufficient to
482 avert the majority of onward transmission in the system (Fig. S8). Our findings offer support for
483 some university policies which continue to mandate asymptomatic surveillance testing even for
484 vaccinated individuals [20], as even modest surveillance efforts still effectively reduced R_E and
485 averted cases in highly vaccinated settings. Our model is structured such that future work could
486 investigate the impact of disparate population sizes, distinct R_0 values reflective of variable
487 contact patterns, and unique vaccination proportions in heterogeneous subgroups within a larger
488 community on longterm epidemic control.

489
490 **Discussion.**

491 We built a stochastic branching process model of SARS-CoV-2 spread in a university
492 environment to advise UC Berkeley on best-practice strategies for effective asymptomatic
493 surveillance in our pop-up IGI testing lab—and to offer a model for other institutions attempting
494 to control the COVID-19 epidemic in their communities. While previous work has explored the
495 isolated effects of specific NPIs—including group association limits [45], symptomatic isolation
496 [2,14–16,25,31], asymptomatic surveillance testing [14–16], and contact tracing [2,25,31]—on
497 COVID-19 control, ours is unique in investigating these interventions simultaneously in a
498 realistic and easily applicable setting. We offer an easy-to-implement modeling tool that can be
499 applied in other educational and workplace settings to provide NPI recommendations tailored to
500 the COVID-19 epidemiology of a specific environment.

501 Results from our analysis of behavior-based NPIs support previous work [2,14–
502 16,25,31,45] in showing that stringent group size limitations to minimize superspreading events
503 and rapid symptom-based isolations offer an effective means of epidemic control in the absence
504 of asymptomatic surveillance testing resources. However, because of the unique natural history
505 of the SARS-CoV-2 virus, for which the majority of transmission events result from
506 asymptomatic or presymptomatic infections [2,31], symptom-based NPIs cannot reduce
507 epidemic spread completely, and small community environments will always remain vulnerable
508 to asymptomatic case importation. Moreover, symptom-based NPIs pose less effective means of
509 epidemic control under scenarios assuming a higher proportion of asymptomatic individuals;
510 empirical evidence suggests that SARS-CoV-2 infection may result in asymptomatic infection in
511 up to nearly 70% of the population in select environments [61]. For this reason, our results

512 emphasize the importance of asymptomatic surveillance testing to prevent ongoing epidemics in
513 universities and other small community environments. As more data becomes available on both
514 the proportion of asymptomatic infections and their contributions to SARS-CoV-2 transmission,
515 the relative importance of group size interventions, symptom-based isolation, and asymptomatic
516 surveillance testing in different epidemiological contexts will be possible to determine from our
517 modeling framework.

518 As with behavioral interventions, our exploration of optimal asymptomatic surveillance
519 testing regimes supports findings that have been published previously but with some key
520 extensions and critical novel insights. As has been recently highlighted [14,15], we find that the
521 most cases are saved under asymptomatic testing regimes that prioritize heightened test
522 frequency and rapid turnaround time over test sensitivity. Importantly, we extend previous work
523 to highlight how more rigorous testing regimes—and those combined with one or more
524 behavioral interventions—greatly reduce variance in daily case counts, leading to more
525 predictable epidemics. We find that the reduction in daily case variation is even more
526 pronounced when test regimes of equivalent frequency are distributed more broadly in time (i.e.
527 tests are offered across more days of the week), thus minimizing the likelihood of compounding
528 transmission chains that may follow upon a superspreading event. Additionally, we demonstrate
529 how a focused stringent testing regime for a subset of “high transmission risk” individuals can
530 effectively control a COVID-19 epidemic for the broader community. Importantly, the extension
531 of our model to heterogenous community dynamics also paves the way for future work that
532 could explicitly model age-structured mixing patterns and infection probabilities by assigning
533 disparate R_0 values and/or distinct viral load trajectories to different community subgroups. For
534 example, students living in university residence halls may experience a higher daily hazard of
535 infection than older adults in lower density housing (as captured in R_0), and young adult
536 infections may manifest with lower viral load trajectories that are more likely to present as
537 asymptomatic. Similarly, future modeling efforts could explore variable infection probabilities
538 and/or viral titer trajectories in individuals infected after vaccination or otherwise. Taken
539 together, our model shows the utility of a multi-faceted approach to COVID-19 control and
540 offers a flexible tool to aid in prioritization of interventions in different university or workplace
541 settings.

542 Finally, our paper presents the only COVID-19 asymptomatic surveillance model
543 published to date that combines asymptomatic testing with contact tracing, thus highlighting the
544 compounding gains effected by these two interventions: contact tracing amplifies the control
545 impacts of both symptom-based and asymptomatic surveillance testing-based isolations, such
546 that even intervention scenarios assuming long delays in isolation after symptom onset or slow
547 turnaround-times for test results can nonetheless greatly reduce the transmission capacity of
548 COVID-19. These findings further emphasize the critical role that asymptomatic surveillance
549 testing will continue to play in ongoing efforts to control COVID-19 epidemics in AY 2021-
550 2022. Even limited asymptomatic surveillance testing can offer substantial gains in case
551 reduction for university and workplace settings with high vaccination rates and/or efficient

552 symptomatic isolation and contact tracing programs in place. Our model allows us to prioritize
553 when and where these gains are most likely to be achieved.

554 Because we do not explicitly model SARS-CoV-2 transmission in a mechanistic,
555 compartmental framework [69,70], our analysis may overlook some more subtle insights into
556 long-term disease dynamics. More complex analyses of interacting epidemics across larger
557 spatial scales or investigations of the duration of immunity will necessitate implementation of a
558 complete compartmental transmission model. However, our use of a stochastic branching
559 process framework makes our model simple to implement and easily transferrable to other semi-
560 contained small community environments, including a wide range of academic settings and
561 workplaces [26]. We make this tool available to others interested in exploring the impacts of
562 targeted public health interventions—in particular, asymptomatic surveillance testing regimes—
563 on COVID-19 control in more specific settings. We at the University of California, Berkeley are
564 committed to maintaining the safest campus environment possible for our community, using all
565 intervention tools at our disposal. We advise those in similar positions at other institutions to
566 employ the behavioral interventions outlined here, in concert with effective asymptomatic
567 surveillance testing regimes, to reduce community epidemics of COVID-19 in their own
568 communities.

569
570
571
572
573
574

575 **Funding.**

576 This work was supported by the Miller Institute for Basic Research at the University of
577 California, Berkeley [fellowship to CEB], the Branco Weiss Society in Science at ETH Zurich
578 [fellowship to CEB], a DARPA PREEMPT Cooperative Grant [no. D18AC00031], a COVID-19
579 Rapid Response Research grant from the Innovative Genomics Institute at the University of
580 California, Berkeley, as well as the NIH [no. R01-GM122061-03] and the NSF EEID program
581 [no. 2011109].

582
583
584
585
586
587
588
589
590
591

592 **References**

- 593 [1] C. Fraser, S. Riley, R.M. Anderson, N.M. Ferguson, Factors that make an infectious
594 disease outbreak controllable, *Proc. Natl. Acad. Sci. U. S. A.* 101 (2004) 6146–6151.
595 doi:10.1073/pnas.0307506101.
- 596 [2] L. Ferretti, C. Wymant, M. Kendall, L. Zhao, A. Nurtay, L. Abeler-Dörner, M. Parker, D.
597 Bonsall, C. Fraser, Quantifying SARS-CoV-2 transmission suggests epidemic control with
598 digital contact tracing, *Science*. 368 (2020) eabb6936. doi:10.1126/science.abb6936.
- 599 [3] E. Petersen, M. Koopmans, U. Go, D.H. Hamer, N. Petrosillo, F. Castelli, M. Storgaard, S.
600 Al Khalili, L. Simonsen, Comparing SARS-CoV-2 with SARS-CoV and influenza
601 pandemics, *Lancet Infect. Dis.* 20 (2020) e238–e244. doi:10.1016/S1473-3099(20)30484-
602 9.
- 603 [4] WHO, Coronavirus disease (COVID-2019) situation reports, (2020).
604 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>
605 (accessed June 30, 2020).
- 606 [5] D.P. Oran, E.J. Topol, Prevalence of asymptomatic SARS-CoV-2 infection: A narrative
607 review, *Ann. Intern. Med.* 173 (2020) 362–367. doi:10.7326/M20-3012.
- 608 [6] K. Mizumoto, K. Kagaya, A. Zarebski, G. Chowell, Estimating the asymptomatic
609 proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess
610 cruise ship, Yokohama, Japan, 2020, *Eurosurveillance*. 25 (2020) 1–5. doi:10.2807/1560-
611 7917.ES.2020.25.10.2000180.
- 612 [7] H. Nishiura, T. Kobayashi, T. Miyama, A. Suzuki, S. Mok Jung, K. Hayashi, R. Kinoshita,
613 Y. Yang, B. Yuan, A.R. Akhmetzhanov, N.M. Linton, Estimation of the asymptomatic
614 ratio of novel coronavirus infections (COVID-19), *Int. J. Infect. Dis.* 94 (2020) 154–155.
615 doi:10.1016/j.ijid.2020.03.020.
- 616 [8] T.A. Treibel, C. Manisty, M. Burton, Á. McKnight, J. Lambourne, J.B. Augusto, X.
617 Couto-Parada, T. Cutino-Moguel, M. Noursadeghi, J.C. Moon, COVID-19: PCR
618 screening of asymptomatic health-care workers at London hospital, *Lancet*. 395 (2020)
619 1608–1610. doi:10.1016/S0140-6736(20)31100-4.
- 620 [9] J.C. Emery, T.W. Russell, Y. Liu, J. Hellewell, C.A.B. Pearson, G.M. Knight, R.M. Eggo,
621 A.J. Kucharski, S. Funk, S. Flasche, R.M.G.J. Houben, K.E. Atkins, P. Klepac, A. Endo,
622 C.I. Jarvis, N.G. Davies, E.M. Rees, S.R. Meakin, A. Rosello, K. van Zandvoort, J.D.
623 Munday, W.J. Edmunds, T. Jombart, M. Auzenbergs, E.S. Nightingale, M. Jit, S. Abbott,
624 D. Simons, N.I. Bosse, Q.J. Leclerc, S.R. Procter, C.J. Villabona-Arenas, D.C. Tully, A.K.
625 Deol, F.Y. Sun, S. Hué, A.M. Foss, K. Prem, G. Medley, A. Gimma, R. Lowe, S. Clifford,
626 M. Quaipe, C. Diamond, H.P. Gibbs, B.J. Quilty, K. O’reilly, The contribution of
627 asymptomatic SARS-CoV-2 infections to transmission on the Diamond Princess cruise
628 ship, *ELife*. 9 (2020) 1–68. doi:10.7554/ELIFE.58699.
- 629 [10] M. Gandhi, D.S. Yokoe, D. V. Havlir, Asymptomatic transmission, the achilles’ heel of
630 current strategies to control COVID-19, *N. Engl. J. Med.* 382 (2020) 2158–2160.
631 doi:10.1056/NEJMe2009758.
- 632 [11] S. Boyles, Covid-19: Asymptomatic transmission fueled nursing home death toll.,
633 *Physicians’ Wkly.* (2020).
- 634 [12] K.Q. Kam, C.F. Yung, L. Cui, R. Lin Tzer Pin, T.M. Mak, M. Maiwald, J. Li, C.Y.

635 Chong, K. Nadua, N.W.H. Tan, K.C. Thoon, A well infant with Coronavirus Disease 2019
636 (COVID-19) with high viral load, *Clin. Infect. Dis.* (2020) ciaa201.
637 doi:10.1093/cid/ciaa201.

638 [13] T. Bai, L. Yao, T. Wei, F. Tian, D.-Y. Jin, L. Chen, M. Wang, Presumed asymptomatic
639 carrier transmission of COVID-19, *J. Am. Med. Assoc.* 382 (2020) 1199–1207.
640 doi:10.1056/NEJMoa2001316.

641 [14] D.B. Larremore, B. Wilder, E. Lester, S. Shehata, J.M. Burke, J.A. Hay, M. Tambe, M.J.
642 Mina, Test sensitivity is secondary to frequency and turnaround time for COVID-19
643 surveillance, *Sci. Adv.* 7 (2021) eabd5393.

644 [15] T. Bergstrom, C.T. Bergstrom, H. Li, Frequency and accuracy of proactive testing for
645 COVID-19, *MedRxiv.* (2020) 2020.09.05.20188839.
646 <https://doi.org/10.1101/2020.09.05.20188839>.

647 [16] A.D. Paltiel, A. Zheng, R.P. Walensky, Assessment of SARS-CoV-2 Screening Strategies
648 to Permit the Safe Reopening of College Campuses in the United States, *JAMA Netw.*
649 *Open.* 3 (2020) e2016818. doi:10.1001/jamanetworkopen.2020.16818.

650 [17] S. Hubler, A. Hartocollis, How Colleges Became the New Covid Hot Spots, *New York*
651 *Times.* (2020).

652 [18] M. Richtel, Looking to Reopen, Colleges Become Labs for Coronavirus Tests and
653 Tracking Apps, *New York Times.* (2020).

654 [19] M.T. Nietzel, As Covid-19 Lingers On, Universities Are Adjusting Their Spring Semester
655 Plans, Often Eliminating Spring Break, *Forbes.* (2020).

656 [20] A. Vaziri, N. Asimov, Stanford among first universities requiring weekly coronavirus
657 testing - even for vaccinated students, *San Fr. Chron.* (2021).

658 [21] T.A. Ghebreyesus, WHO director-general’s opening remarks at the media briefing on
659 COVID-19, (2020). [https://www.who.int/dg/speeches/detail/who-director-general-s-](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)
660 [opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020).

661 [22] A.M. Amen, K.W. Barry, C.E. Brook, J.M. Boyle, S. Choo, L.T. Cornmesser, D.J.
662 Dilworth, J.A. Doudna, A.J. Ehrenberg, I. Fedrigo, S.E. Friedline, T.G.W. Graham, R.
663 Green, J.R. Hamilton, A. Hirsh, M.L. Hochstrasser, D. Hockemeyer, N. Krishnappa, A.
664 Lari, H. Li, E. Lin-Shiao, T. Lu, E.F. Lyons, K.G. Mark, L.A. Martell, A.R.O. Martins,
665 S.L. McDevitt, P.S. Mitchell, E.A. Moehle, C. Naca, D. Nandakumar, E. O’Brien, D.J.
666 Pappas, K. Pestal, D.L. Quach, B.E. Rubin, R. Sachdeva, E.C. Stahl, A.M. Syed, I.-L.
667 Tan, A.L. Tollner, C.A. Tsuchida, C.K. Tsui, T.K. Turkalo, F.D. Urnov, M.B. Warf, O.N.
668 Whitney, L.B. Witkowsky, Blueprint for a pop-up SARS-CoV-2 testing lab, *Nat.*
669 *Biotechnol.* 38 (2020) 791–797. doi:10.1038/s41587-020-0583-3.

670 [23] A.J. Ehrenberg, E.A. Moehle, C.E. Brook, A.H.D. Cate, L.B. Witkowsky, R. Sachdeva, A.
671 Hirsch, K. Barry, J.R. Hamilton, E. Lin-Shiao, S. McDevitt, L. Valentin-Alvarado, K.N.
672 Letourneau, L. Hunter, K. Pestal, P.A. Frankino, A. Murley, D. Nandakumar, E.C. Stahl,
673 C.A. Tsuchida, H.K. Gildea, A.G. Murdock, M.L. Hochstrasser, L. Bardet, C. Sherry,
674 T.I.S.-C.-2 T. Consortium, A. Harte, G. Nicolette, P. Giannikopoulos, D. Hockemeyer, M.
675 Petersen, F.D. Urnov, B.R. Ringeisen, M. Boots, J.A. Doudna, Launching a saliva-based
676 SARS-CoV-2 surveillance testing program on a university campus, *MedRxiv.* (2021) 1–
677 24.

- 678 [24] UC Berkeley COVID-19 Dashboard, (n.d).
679 [https://coronavirus.berkeley.edu/dashboard/?utm_source=Response+and+Recovery&utm_campaign=5247da06c4-](https://coronavirus.berkeley.edu/dashboard/?utm_source=Response+and+Recovery&utm_campaign=5247da06c4-Response_Recovery_2020_10_09&utm_medium=email&utm_term=0_940930e328-5247da06c4-389116456)
680 [Response_Recovery_2020_10_09&utm_medium=email&utm_term=0_940930e328-](https://coronavirus.berkeley.edu/dashboard/?utm_source=Response+and+Recovery&utm_campaign=5247da06c4-Response_Recovery_2020_10_09&utm_medium=email&utm_term=0_940930e328-5247da06c4-389116456)
681 [5247da06c4-389116456](https://coronavirus.berkeley.edu/dashboard/?utm_source=Response+and+Recovery&utm_campaign=5247da06c4-Response_Recovery_2020_10_09&utm_medium=email&utm_term=0_940930e328-5247da06c4-389116456) (accessed October 1, 2020).
682
- 683 [25] C.M. Peak, R. Kahn, Y.H. Grad, L.M. Childs, R. Li, M. Lipsitch, C.O. Buckee, Individual
684 quarantine versus active monitoring of contacts for the mitigation of COVID-19: a
685 modelling study, *Lancet Infect. Dis.* 3099 (2020) 2020.03.05.20031088.
686 doi:10.1101/2020.03.05.20031088.
- 687 [26] C.E. Brook, G.R. Northrup, M. Boots, Code for “Optimizing COVID-19 control with
688 asymptomatic surveillance testing in a university environment,” (2020).
689 doi:10.5281/zenodo.4131223.
- 690 [27] R. of the U. of California, UC issues final COVID-19 vaccination policy, Ucnet. (2021).
691 <https://ucnet.universityofcalifornia.edu/news/2021/07/ucs-covid-19-vaccine-policy.html>.
- 692 [28] F.P. Polack, S.J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J.L. Perez, G.
693 Pérez Marc, E.D. Moreira, C. Zerbini, R. Bailey, K.A. Swanson, S. Roychoudhury, K.
694 Koury, P. Li, W. V. Kalina, D. Cooper, R.W. Frenck, L.L. Hammitt, Ö. Türeci, H. Nell,
695 A. Schaefer, S. Ünal, D.B. Tresnan, S. Mather, P.R. Dormitzer, U. Şahin, K.U. Jansen,
696 W.C. Gruber, Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine, *N. Engl. J.*
697 *Med.* 383 (2020) 2603–2615. doi:10.1056/nejmoa2034577.
- 698 [29] S.M. Kissler, C. Tedijanto, E. Goldstein, Y.H. Grad, M. Lipsitch, Projecting the
699 transmission dynamics of SARS-CoV-2 through the postpandemic period, *Science.* 5793
700 (2020) 1–13.
- 701 [30] C.M. Saad-Roy, C.E. Wagner, R.E. Baker, S.E. Morris, J.J. Farrar, A.L. Graham, S.A.
702 Levin, M.J. Mina, C.J.E. Metcalf, B.T. Grenfell, Immune life history, vaccination, and the
703 dynamics of SARS-CoV-2 over the next 5 years, *Science.* 21 (2020) 1–9.
704 doi:10.1155/2010/706872.
- 705 [31] J. Hellewell, S. Abbott, A. Gimma, N.I. Bosse, C.I. Jarvis, T.W. Russell, J.D. Munday,
706 A.J. Kucharski, W.J. Edmunds, F. Sun, S. Flasche, B.J. Quilty, N. Davies, Y. Liu, S.
707 Clifford, P. Klepac, M. Jit, C. Diamond, H. Gibbs, K. van Zandvoort, S. Funk, R.M. Eggo,
708 Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts, *Lancet*
709 *Glob. Heal.* 8 (2020) e488–e496. doi:10.1016/S2214-109X(20)30074-7.
- 710 [32] A. Endo, S. Abbott, A.J. Kucharski, S. Funk, Estimating the overdispersion in COVID-19
711 transmission using outbreak sizes outside China, *Wellcome Open Res.* 5 (2020) 67.
712 doi:10.12688/wellcomeopenres.15842.3.
- 713 [33] Y. Liu, J. Rocklöv, The reproductive number of the Delta variant of SARS-CoV-2 is far
714 higher compared to the ancestral SARS-CoV-2 virus, *J. Travel Med.* 3 (2021) 584–586.
715 doi:10.46234/ccdcw2021.148.
- 716 [34] University of Alabama System COVID-19 Dashboard, (n.d.).
- 717 [35] C.B.F. Vogels, A.F. Brito, A.L. Wyllie, J.R. Fauver, I.M. Ott, C.C. Kalinich, M.E.
718 Petrone, A. Casanovas-Massana, M. Catherine Muenker, A.J. Moore, J. Klein, P. Lu, A.
719 Lu-Culligan, X. Jiang, D.J. Kim, E. Kudo, T. Mao, M. Moriyama, J.E. Oh, A. Park, J.
720 Silva, E. Song, T. Takahashi, M. Taura, M. Tokuyama, A. Venkataraman, O. El Weizman,

- 721 P. Wong, Y. Yang, N.R. Cheemarla, E.B. White, S. Lapidus, R. Earnest, B. Geng, P.
722 Vijayakumar, C. Odio, J. Fournier, S. Bermejo, S. Farhadian, C.S. Dela Cruz, A. Iwasaki,
723 A.I. Ko, M.L. Landry, E.F. Foxman, N.D. Grubaugh, Analytical sensitivity and efficiency
724 comparisons of SARS-CoV-2 RT-qPCR primer-probe sets, *Nat. Microbiol.* (2020).
725 doi:10.1038/s41564-020-0761-6.
- 726 [36] N.R. Meyerson, Q. Yang, S.K. Clark, C.L. Paige, W.T. Fattor, A.R. Gilchrist, A.
727 Barbachano-Guerrero, S.L. Sawyer, A community-deployable SARS-CoV-2 screening
728 test using raw saliva with 45 minutes sample-to-results turnaround, *MedRxiv.* (2020)
729 2020.07.16.20150250. doi:10.1101/2020.07.16.20150250.
- 730 [37] V.L. Dao Thi, K. Herbst, K. Boerner, M. Meurer, L.P.M. Kremer, D. Kirrmaier, A.
731 Freistaedter, D. Papagiannidis, C. Galmozzi, M.L. Stanifer, S. Boulant, S. Klein, P.
732 Chlanda, D. Khalid, I.B. Miranda, P. Schnitzler, H.G. Kräusslich, M. Knop, S. Anders, A
733 colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in
734 clinical samples, *Sci. Transl. Med.* 12 (2020). doi:10.1126/SCITRANSLMED.ABC7075.
- 735 [38] L. Bordi, A. Piralla, E. Lalle, F. Giardina, F. Colavita, M. Tallarita, G. Sberna, F. Novazzi,
736 S. Meschi, C. Castilletti, A. Brisci, G. Minnucci, V. Tettamanzi, F. Baldanti, M.R.
737 Capobianchi, Rapid and sensitive detection of SARS-CoV-2 RNA using the Simplexa™
738 COVID-19 direct assay, *J. Clin. Virol.* 128 (2020). doi:10.1016/j.jcv.2020.104416.
- 739 [39] M. Fiedler, C. Holtkamp, U. Dittmer, O.E. Anastasiou, Performance of the LIAISON
740 SARS-CoV-2 antigen assay vs. SARS-CoV-2 RT-PCR, *Pathogens.* 10 (2021) 1–9.
741 doi:10.3390/pathogens10060658.
- 742 [40] S. Jumar, S. Jha, S.K. Rai, Significance of super spreader events in COVID-19, *Indian J.*
743 *Public Health.* 64 (2020) 139–141.
- 744 [41] B.M. Althouse, E.A. Wenger, J.C. Miller, S. V. Scarpino, A. Allard, L. Hébert-Dufresne,
745 H. Hu, Stochasticity and heterogeneity in the transmission dynamics of SARS-CoV-2,
746 *ArXiv.* (2020) 1–10. <http://arxiv.org/abs/2005.13689>.
- 747 [42] L. Hébert-Dufresne, B.M. Althouse, S. V. Scarpino, A. Allard, Beyond R0: Heterogeneity
748 in secondary infections and probabilistic epidemic forecasting, *J. R. Soc. Interface.* 17
749 (2020) 20200393. doi:10.1101/2020.02.10.20021725.
- 750 [43] Y. Liu, R.M. Eggo, A.J. Kucharski, Secondary attack rate and superspreading events for
751 SARS-CoV-2, *Lancet.* 395 (2020) e47. doi:10.1016/S0140-6736(20)30462-1.
- 752 [44] D.C. Adam, P. Wu, J.Y. Wong, E.H.Y. Lau, T.K. Tsang¹, S. Cauchemez, G.M. Leung,
753 B.J. Cowling, B.J.C. * Cauchemez³, Gabriel M. Leung¹ *, Clustering and superspreading
754 potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in
755 Hong Kong, *J. Vis. Lang. Comput.* 11 (2559) 55. [https://www.m-](https://www.m-culture.go.th/mculture_th/download/king9/Glossary_about_HM_King_Bhumibol_Adulya_dej's_Funeral.pdf)
756 [culture.go.th/mculture_th/download/king9/Glossary_about_HM_King_Bhumibol_Adulya](https://www.m-culture.go.th/mculture_th/download/king9/Glossary_about_HM_King_Bhumibol_Adulya_dej's_Funeral.pdf)
757 [dej's_Funeral.pdf](https://www.m-culture.go.th/mculture_th/download/king9/Glossary_about_HM_King_Bhumibol_Adulya_dej's_Funeral.pdf).
- 758 [45] M.P. Kain, M.L. Childs, A.D. Becker, E.A. Mordecai, Chopping the tail: how preventing
759 superspreading can help to maintain COVID-19 control., *MedRxiv Prepr. Serv. Heal. Sci.*
760 (2020). doi:10.1101/2020.06.30.20143115.
- 761 [46] R. Laxminarayan, B. Wahl, S.R. Dudala, K. Gopal, C. Mohan, S. Neelima, K.S.J. Reddy,
762 J. Radhakrishnan, J.A. Lewnard, Epidemiology and transmission dynamics of COVID-19
763 in two Indian states, *Science.* 28 (2020) eabd7672.

- 764 <http://journals.sagepub.com/doi/10.1177/1120700020921110%0Ahttps://doi.org/10.1016/j>
765 [.reuma.2018.06.001%0Ahttps://doi.org/10.1016/j.arth.2018.03.044%0Ahttps://reader.elsevier.com/reader/sd/pii/S1063458420300078?token=C039B8B13922A2079230DC9AF11A333E295FCD8](https://doi.org/10.1016/j.arth.2018.03.044%0Ahttps://reader.elsevier.com/reader/sd/pii/S1063458420300078?token=C039B8B13922A2079230DC9AF11A333E295FCD8).
- 768 [47] M.S.Y. Lau, B. Grenfell, M. Thomas, M. Bryan, K. Nelson, B. Lopman, Characterizing
769 superspreading events and age-specific infectiousness of SARS-CoV-2 transmission in
770 Georgia, USA, *Proc. Natl. Acad. Sci. U. S. A.* 117 (2020) 22430–22435.
771 doi:10.1073/pnas.2011802117.
- 772 [48] A. Goyal, D.B. Reeves, E. Fabian Cardozo-Ojeda, J.T. Schiffer, B.T. Mayer, Wrong
773 person, place and time: viral load and contact network structure predict SARS-CoV-2
774 transmission and super-spreading events, *MedRxiv.* (2020) 2020.08.07.20169920.
775 <https://www.medrxiv.org/content/10.1101/2020.08.07.20169920v2%0Ahttps://www.medrxiv.org/content/10.1101/2020.08.07.20169920v2.abstract>.
- 777 [49] B.F. Nielsen, K. Sneppen, COVID-19 superspreading suggests mitigation by social
778 network modulation, *MedRxiv.* (2020) 2020.09.15.20195008.
779 <http://medrxiv.org/content/early/2020/10/04/2020.09.15.20195008.abstract>.
- 780 [50] A.S. Perelson, Modelling viral and immune system dynamics, *Nat. Rev. Immunol.* 2
781 (2002) 28–36. doi:10.1038/nri700.
- 782 [51] D.D. Ho, A.U. Neumann, A.S. Perelson, W. Chen, J.M. Leonard, M. Markowitz, Rapid
783 turnover of plasma virions and CD4 lymphocytes in HIV-1 infection, *Nature.* 373 (1995)
784 123–126. doi:10.1038/373123a0.
- 785 [52] M.A. Nowak, R.M. May, *Virus Dynamics: Mathematical Principles of Immunology and*
786 *Virology*, Oxford University Press, Oxford, UK, 2000.
- 787 [53] R. Ke, C. Zitzmann, R.M. Ribeiro, A.S. Perelson, Kinetics of SARS-CoV-2 infection in
788 the human upper and lower respiratory tracts and their relationship with infectiousness,
789 *MedRxiv.* (2020) 2020.09.25.20201772.
790 <http://medrxiv.org/content/early/2020/09/27/2020.09.25.20201772.abstract>.
- 791 [54] J. Schwab, L.B. Balzer, E. Geng, J. Peng, M.L. Petersen, Local Epidemic Modeling for
792 Management and Action, (n.d.). <https://localepi.github.io/LEMMA/>.
- 793 [55] L.M. Kucirka, S.A. Lauer, O. Laeyendecker, D. Boon, J. Lessler, Variation in false-
794 negative rate of reverse transcriptase polymerase chain reaction–based SARS-CoV-2 tests
795 by time since exposure, *Ann. Intern. Med.* (2020). doi:10.7326/m20-1495.
- 796 [56] R. Wölfel, V.M. Corman, W. Guggemos, M. Seilmaier, S. Zange, M.A. Müller, D.
797 Niemeyer, T.C. Jones, P. Vollmar, C. Rothe, M. Hoelscher, T. Bleicker, S. Brünink, J.
798 Schneider, R. Ehmann, K. Zwirgmaier, C. Drosten, C. Wendtner, Virological assessment
799 of hospitalized patients with COVID-2019, *Nature.* 581 (2020) 465–469.
800 doi:10.1038/s41586-020-2196-x.
- 801 [57] K. Quicke, E. Gallichotte, N. Sexton, M. Young, A. Janich, G. Gahm, E.J. Carlton, N.
802 Ehrhart, G.D. Ebel, Longitudinal surveillance for SARS-CoV-2 RNA among
803 asymptomatic staff in five Colorado skilled nursing facilities: Epidemiologic, virologic
804 and sequence analysis, *MedRxiv.* (2020). doi:10.1101/2020.06.08.20125989v1.
- 805 [58] B. La Scola, M. Le Bideau, J. Andreani, V.T. Hoang, C. Grimaldier, P. Colson, P. Gautret,
806 D. Raoult, Viral RNA load as determined by cell culture as a management tool for

807 discharge of SARS-CoV-2 patients from infectious disease wards, *Eur. J. Clin. Microbiol.*
808 *Infect. Dis.* 39 (2020) 1059–1061. doi:10.1007/s10096-020-03913-9.

809 [59] M.H. Chitwood, M. Russi, K. Gunasekera, J. Havumaki, V.E. Pitzer, J.L. Warren, D.M.
810 Weinberger, T. Cohen, N.A. Menzies, Menzies3, Bayesian nowcasting with adjustment
811 for delayed and incomplete reporting to estimate COVID-19 infections in the United
812 States, *MedRxiv.* 20 (2020) 1–6. doi:10.18907/jjsre.20.7_624_5.

813 [60] U.B. Public Affairs, Social gatherings produce increase in student COVID-19 cases,
814 *Berkeley News.* (2020).

815 [61] P. Poletti, M. Tirani, D. Cereda, F. Trentini, G. Guzzetta, G. Sabatino, V. Marziano, A.
816 Castrofino, F. Grosso, G. Del Castillo, R. Piccarreta, A.L.C.-19 T. Force, A. Andreassi, A.
817 Melegaro, M. Gramegna, M. Ajelli, S. Merler, Probability of symptoms and critical
818 disease after SARS-CoV-2 infection, *ArXiv.* (2020). <http://arxiv.org/abs/2006.08471>.

819 [62] K.J. Wu, 'It's Like Groundhog Day': Coronavirus Testing Labs Again Lack Key Supplies,
820 *New York Times.* (2020).

821 [63] R. Meyer, A.C. Madrigal, The Plan That Could Give Us Our Lives Back, *Atl.* (2020).

822 [64] J.L. Geoghegan, X. Ren, M. Storey, J. Hadfield, L. Jelley, S. Jefferies, J. Sherwood, S.
823 Paine, S. Huang, J. Douglas, F.K. Mendes, A. Sporle, M.G. Baker, D.R. Murdoch, N.
824 French, C.R. Simpson, D. Welch, A.J. Drummond, E.C. Holmes, S. Duchêne, J. de Ligt,
825 Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in
826 Aotearoa New Zealand, *Nat. Commun.* 11 (2020) 1–7. doi:10.1038/s41467-020-20235-8.

827 [65] C. of B.P.H. Officer, Order of the Health Officer of the City of Berkeley Imposing
828 Measure Necessary to Control the Spread of COVID-19, 2020.

829 [66] U.S.D. Health, CA Notify, (2020). <https://canotify.ca.gov/> (accessed December 21, 2020).

830 [67] C. de Rio, P.N. Malani, S.B. Omer, Confronting the Delta variant of SARS-CoV-2,
831 summer 2021, *J. Am. Med. Assoc.* 385 (2021) 1244–1246. doi:10.1056/nejmc2111462.

832 [68] A. Thomason, B. O'Leary, Here's a List of Colleges That Require Students or Employees
833 to Be Vaccinated Against Covid-19, *Chronical High. Educ.* (2021).
834 [https://www.chronicle.com/blogs/live-coronavirus-updates/heres-a-list-of-colleges-that-](https://www.chronicle.com/blogs/live-coronavirus-updates/heres-a-list-of-colleges-that-will-require-students-to-be-vaccinated-against-covid-19?bc_nonce=7dz1p1qvlwvwnq51dsjs6jm&cid=reg_wall_signup)
835 [will-require-students-to-be-vaccinated-against-covid-](https://www.chronicle.com/blogs/live-coronavirus-updates/heres-a-list-of-colleges-that-will-require-students-to-be-vaccinated-against-covid-19?bc_nonce=7dz1p1qvlwvwnq51dsjs6jm&cid=reg_wall_signup)
836 [19?bc_nonce=7dz1p1qvlwvwnq51dsjs6jm&cid=reg_wall_signup](https://www.chronicle.com/blogs/live-coronavirus-updates/heres-a-list-of-colleges-that-will-require-students-to-be-vaccinated-against-covid-19?bc_nonce=7dz1p1qvlwvwnq51dsjs6jm&cid=reg_wall_signup).

837 [69] R.M. Anderson, R.M. May, M.C. Boily, G.P. Garnett, J.T. Rowley, The spread of HIV-1
838 in Africa: sexual conflict patterns and the predicted demographic impact of AIDS, *Nature.*
839 352 (1991) 581–589.

840 [70] W.O. Kermack, A.G. McKendrick, A contribution to the mathematical theory of
841 epidemics, *Proc. R. Soc. London, Ser. A.* 115 (1927) 700–721.

842

843

844

1 **Supplementary Appendix.**

3 **Text S1. *Model Description.***

4 Our publicly-available Github repository (1) provides opensource code to reproduce all
5 simulations and analyses presented in our paper. We summarize the practical implementation
6 details of our modeling design for ease-of-access here.

7 Our model takes the form of a stochastic branching process model, in which a subset
8 population of exposed individuals (0.5%, derived from the mean percentage of positive tests in
9 our UC Berkeley community (2)) is introduced into a hypothetical 20,000 person community that
10 approximates the campus utilization goals for our university in spring 2021. The model code
11 builds up to a single function `replicate.epidemic()` which runs a specified number of stochastic
12 simulations from a defined parameter set, using the function `simulate.epidemic()`. Within the
13 `simulate.epidemic()` function, we first construct a population of 20,000 persons in the sub-
14 function, `initiate.pop()`. Within this initiation function, each person in our population is
15 individually numbered, assigned a viral titer trajectory that will be followed if that individual
16 becomes infected (Text B), and assigned a suite of disease metrics drawn stochastically from a
17 specified set of parameter distributions, as outlined in Text S3.

19 **Text S2. *Within-host viral dynamics***

20 *Titer Trajectories.*

21 For computational efficiency, we pre-generated 20,000 50-day individual titer trajectories
22 and saved them as an .Rdata file, "titer.dat.20K.Rdata". To generate these trajectories, we used
23 a within-host viral kinetics model structured after the classic target cell model (3–5). Code for
24 this model is available in the `model-sandbox` folder of our Github release, under file `viral-
25 load.R`, which iterates the following simple model and parameter values derived from Ke et al.
26 (2020), describing the dynamics of SARS-CoV-2 proliferation in the upper respiratory tract (6):
27

$$28 \frac{dT_C}{dt} = -\beta T_C V$$

$$29 \frac{dE}{dt} = \beta T_C V - kE$$

$$30 \frac{dI}{dt} = kE - \delta I$$

$$31 \frac{dV}{dt} = pI - cV$$

32
33 where T_C corresponds to the target cell population, β is the transmission rate of free virus to
34 target cell invasion, k corresponds to the inverse of the duration of the virus eclipse phase, and δ
35 corresponds to the inverse of the incubation period of an infected cell. p then gives the burst size
36 of a virus-infected cell and c equals the inverse of the lifespan of free virus subject to natural

37 virus mortality and immune predation. Parameter values used to generate each titer trajectory
38 (with a standard deviation of .1x the value of each parameter introduced to add stochasticity in
39 each iteration) are derived from Ke et al. (2020) (6), after fitting this model to individual patient
40 data tracking viral loads through time in the upper respiratory tract of SARS-CoV-2-infected
41 individuals:

42

43 *starting conditions:* $T_C = 4 * 10^6$; $E = 0$; $I = 1$; $V = 0$

44 *parameter values:* $\beta = 1.9 * 10^{-6}$; $k = 4$; $c = 10$; $\delta = 1.9$; $p = 51.4$

45

46 Note that Ke et al. (2020) (6) also explore the within-host dynamics of SARS-CoV-2 infection in
47 the lower respiratory tract; however, since we model human-to-human transmissibility as
48 inferred by viral load in nasopharyngeal swab samples (which better reflect the viral load in the
49 upper respiratory tract), we ignore the lower respiratory dynamics here.

50

51 *Infectivity by Viral Load.*

52 After Ke et al. (2020) (6), we next estimated the probability of infection given contact at a
53 specific viral load, using a Michaelis-Menton-like function. Following Ke et al. (2020), we
54 described the probability this probability as:

55
$$P(\text{transmission}) = 1 - \exp\left(-1 * \left(\theta \left(\frac{V}{V + K_m}\right)\right)\right)$$

56 where K_m corresponds to the saturation constant by which proportional gains in infectiousness
57 with viral load diminish at increasingly high viral titers and θ is a constant, such that the
58 maximum transmission capacity at any moment equals $1 - e^{-\theta}$. Ke et al. (2020) modeled a
59 constant hazard of contact events for infectious individuals and therefore fixed θ at a value of
60 0.05, corresponding to a ~5% probability of a given contact resulting in transmission. Because
61 we draw possible transmissions events from a negative binomial SARS-CoV-2 R_0 distribution,
62 (mean= 2.5 and $k=0.10$ (7)) but ultimately know that R_E for our university environment should
63 have a value of just above one (8), we instead fixed θ at a value of 0.72, corresponding to a
64 ~51% probability of a given contact resulting in transmission, thus effectively halving R_0
65 to generate R_E . The exact probability varied as a function of the timing of each contact event across
66 the trajectory of within-host viral load, with transmissions favored earlier in an infection
67 trajectory when viral load peaks (9).

68

69 **Text S3. Individual disease metrics**

70 Figures in our paper are derived from 100x replications of each set of parameter values, which
71 we manipulate to explore a range of non-pharmaceutical interventions (NPIs) to combat COVID-
72 19 dynamics in our system. Our flexible model allows for the introduction of NPIs for COVID-
73 19 control in four different forms: (1) group size limits, (2) symptom-based isolations, (3)
74 surveillance testing isolations, and (4) contact tracing isolations that follow after cases are
75 identified through screening from symptomatic or surveillance testing. These interventions

76 modify the suite of disease metrics drawn upon model initiation for each numbered individual in
77 the dataset. We summarize the disease metrics drawn at initiation for all members of the
78 population here:

- 79 • **Time of next test:** allocated based on the selected asymptomatic surveillance testing regime.
80 We assume the week starts with day 1 on Saturday and day 7 on Friday. If $n.test.days = 2$, then
81 tests are distributed on Monday (day 3) and Friday (day 7) of each week. As timesteps
82 advance and individuals reach their respective test days, the next test day is updated based on
83 the testing regime (if semi-weekly, the next test day is advanced 3 days; if weekly, the next
84 test day is advanced 7 days; if every-two-weeks, the next test day is advanced 14 days).
- 85 • **Beginning/end time of test sensitivity:** based on test limit of detection (LOD) as specified at
86 model outset, this corresponds to the timestep post exposure at which an individual viral titer
87 crosses the threshold for being detectable by the chosen test, both as titers increase at the
88 beginning of a disease trajectory and decrease at the end.
- 89 • **Adherence with testing regime:** Y/N, allocated randomly across individuals based on the
90 proportion of the population modeled as complying with the surveillance testing intervention
91 (90% of individuals in all scenarios modeled in our paper).
- 92 • **Adherence with group limit:** Y/N, allocated randomly across individuals based on the
93 proportion of the population modeled as complying with the group size limits imposed at
94 outset (90% of individuals in all scenarios modeled in our paper; see ‘number of potential
95 onward cases generated for’ for how group size interacts with cases).
- 96 • **Adherence with contact tracing regimen:** Y/N, allocated randomly across individuals based
97 on the proportion of the population modeled as complying with the contact tracing
98 intervention imposed at outset (90% of individuals in all scenarios modeled in our paper).
- 99 • **Time of symptom onset:** determined by randomly drawing a titer limit for symptom onset for
100 each individual from a lognormal distribution with a mean of $1e+05$ cp/μl RNA and a
101 standard deviation of $1e+04$ cp/μl (10–12). The timing of symptom onset then corresponds to
102 the time post-exposure at which each individual’s titer trajectory crosses the corresponding
103 titer limit. According to this approach, under default parameter values, symptom onset
104 occurred between 2 to 4 days post-exposure in our model, and ~32% of the population never
105 presented with symptoms at all (Fig. 1, main text).
- 106 • **Time of symptom-based isolation:** based on delay lag post-symptom onset, drawn from a
107 lognormal distribution with a mean of the specified number of days of symptom isolation lag
108 (1-5 or infinity) and a standard deviation of 0.5 days.
- 109 • **Time of tracing-based isolation:** based on contact tracing lag for those adhering to the
110 contact tracing regimen in place. Parameter must be updated with each timestep until
111 individual becomes infected; value then becomes fixed at time of infector isolation, plus
112 corresponding lag drawn from a lognormal distribution with a mean of one day and a standard
113 deviation of 0.5 days.

- 114 • **Time of testing-based isolation:** based on turnaround time to isolation post testing, drawn
115 from a lognormal distribution with a mean of the specified number of delay days (1-5, 10, or
116 infinity) and a standard deviation of 0.5 days. Parameter is updated when ‘time of next test’ is
117 updated for each individual in our model.
- 118 • **Disease status:** ‘susceptible’ = 0, ‘exposed’ = 3, ‘infectious’ = 1, ‘recovered’ = 5,
119 ‘vaccinated’= 6. At onset, all individuals are modeled as susceptible, excepting the 0.5%
120 which are introduced as infectious (1) to seed the epidemic and the ‘prop-vaccinated’, a
121 parameter encoding the proportion of the target population that is vaccinated prior to the start
122 of epidemic simulations. We additionally encode a ‘prop-breakthrough’ parameter which
123 corresponds to the proportion of vaccinated individuals who experience breakthrough
124 infections. In simulations presented in our paper, 95% of vaccinated individuals are treated as
125 if fully immune, while 5% of individuals experience breakthrough infections; these
126 breakthrough cases are modeled stochastically, based on probability at the timestep in which
127 each possible infection encounter occurs.

128 **Number of potential onward cases generated:** Several figures in the main text of our
129 manuscript present the R_E reduction capacity of a specified intervention, which we calculate
130 as the difference between the average of the number of potential onward cases generated and
131 the number of actual onward cases generated for each individual after an intervention is
132 adopted. To compute the number of potential onward cases generated for each individual, we
133 first draw a number of possible cases from a negative binomial distribution with a mean of 2.5
134 and a dispersion parameter (k) of 0.10, as estimated for SARS-CoV-2 (7) (or with a mean of 6
135 in later simulations to represent the heightened transmissibility of the Delta variant (13)).
136 Next, we assume that a minority of transmission events will be lost to the external
137 environment through contacts between UC Berkeley students and members from the outside
138 community. We do not track these ‘lost cases’ but instead simply reduce the total number of
139 potential onward cases to the proportion constrained within UCB: 90% in simulations
140 presented in the main text and 50% in the sensitivity analysis presented in Fig. S5.

141 Then, we draw a number of possible onward transmission events for the remaining cases
142 for each infectious individual from a simple Poisson distribution with $\lambda = 3$, signifying the
143 average number of possible encounters (i.e. cross-household dining, shared car rides, indoor
144 meetings, etc.) per person that could result in transmission. We then distribute each infectious
145 person’s original number of R_0 -derived potential cases among these events at random,
146 ensuring that multiple transmissions are possible at a single event; the most extreme
147 superspreading events thus occur when persons with heterogeneously high infectiousness
148 draw a large number of potential cases, which are concentrated within a relatively small
149 number of discrete transmission events. For example, if an infectious individual draws an R_0
150 value of 16 and an event number value of 4, then those 16 potential infections are randomly
151 distributed among 4 events.

152

153 Next, we use published estimates of the generation time of onward transmission events for
154 SARS-CoV-2 infection to draw event times for each event, based on a weibull distribution
155 with a shape parameter = 2.826 and a scale parameter = 5.665, as specified in Ferretti et al.
156 (2020) (9). Following the above example, 4 discrete generation times would be assigned to
157 cases across the 4 pre-allocated events.

158 Since each individual is already pre-assigned a within-host viral titer trajectory in our
159 modeling framework, we next examine the viral load specified at the generation time of each
160 transmission event and determine if each case assigned to that event actually occurs. Each
161 case is considered individually, and the probability of transmission is computed stochastically
162 based on the value of the individual's viral titer at the time of the event (higher titer infections
163 are more likely to generate onward transmission events) (Text S2). In the above example, all
164 16 possible transmissions would be individually assessed, though several would have the
165 same titer, corresponding to the infectious person's titer at the time point of each contact event
166 (4 possible). Since our maximum probability of a case occurring at max viral load is ~51%
167 (Text S2), our original R_0 -derived cases are here halved, resulting in an average of 1.05
168 onward transmission events per infectious individual (or just under 3 in the case of Delta
169 simulations) in the absence of the NPIs examined here (but reflecting social distancing and
170 mask wearing), which, as specified in the main text, is in line with current estimates from
171 Alameda County, CA (8).

172 For the purposes of our example, let's assume that 10 of those possible 16 cases occur,
173 allocated across 4 different events, with 7 cases at one event and one case each at 3 other
174 events.

- 175 • **Number of actual onward cases generated:** From the number of possible cases generated,
176 we next apply the relevant intervention and iterate forward in time to determine the actual
177 number of cases generated by each infectious individual across the time course of our
178 modeled epidemics. For symptom and surveillance testing-based isolations, as well as contact
179 tracing, no cases are generated if an infectious individual is isolated prior to the generation
180 time of any possible onward cases. For NPIs in the form of group size limits, case reduction in
181 our model is performed prior to the initiation of the epidemic time series, and case numbers
182 for each transmission event are truncated at the intervention limit.

183 Again following the example listed above, if we imagine that the imposed group size limit
184 is 6, then the 7 cases assigned to a single event will be truncated to 6, meaning that 9 out of
185 the 10 potential cases are allowed to occur after the intervention. Our model is conservative in
186 assessing the impact of a group-size intervention by allowing some portion of those
187 superspreading cases to occur, rather than assuming that a group size limit-abiding infectious
188 individual does not attend larger-than-allowable events altogether. Because only 90% of the
189 population adheres to group size intervention in any given simulation (or 50% in sensitivity
190 analyses; see Fig. S1), some proportion of large superspreading events will still take place at
191 random, even after NPIs are imposed.

192 Following onset of infection, the timings of symptom-, tracing-, and asymptomatic testing-based
193 isolations are then compared and the earliest time is selected as the actual mechanism (if any) of
194 isolation for that individual. The number of actual onward cases generated is then updated if
195 isolation occurs prior to some new case generations. Additionally, all individuals identified as
196 infectious are additionally assigned the following metrics:

- 197 • **Isolation time of infector**
- 198 • **Source of infection** (external Alameda County vs. UC Berkeley community member)
- 199 • **ID number of infector**, if from UC Berkeley


200 The cycle then repeats in the next timestep when all “actual infections” for each infectious
201 individual are then assigned to new susceptible individuals. The epidemic continues with
202 updated parameters for all newly exposed individuals until either the end of the time series is
203 reached or no more susceptible individuals remain in the population.

204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230

231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270


References for Supplementary File 1.

1. Brook CE, Northrup GR, Boots M (2020) Code for “Optimizing COVID-19 control with asymptomatic surveillance testing in a university environment.” doi:10.5281/zenodo.4131223.
2. UC Berkeley COVID-19 Dashboard Available at: https://coronavirus.berkeley.edu/dashboard/?utm_source=Response+and+Recovery&utm_campaign=5247da06c4-Response_Recovery_2020_10_09&utm_medium=email&utm_term=0_940930e328-5247da06c4-389116456 [Accessed October 1, 2020].
3. Perelson AS (2002) Modelling viral and immune system dynamics. *Nat Rev Immunol* 2(1):28–36.
4. Ho DD, et al. (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. *Nature* 373:123–126.
5. Nowak MA, May RM (2000) *Virus Dynamics: Mathematical Principles of Immunology and Virology* (Oxford University Press, Oxford, UK).
6. Ke R, Zitzmann C, Ribeiro RM, Perelson AS (2020) Kinetics of SARS-CoV-2 infection in the human upper and lower respiratory tracts and their relationship with infectiousness. *medRxiv*:2020.09.25.20201772.
7. Endo A, Abbott S, Kucharski AJ, Funk S (2020) Estimating the overdispersion in COVID-19 transmission using outbreak sizes outside China. *Wellcome Open Res* 5:67.
8. Schwab J, Balzer LB, Geng E, Peng J, Petersen ML Local Epidemic Modeling for Management and Action. Available at: <https://localepi.github.io/LEMMA/>.
9. Ferretti L, et al. (2020) Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. *Science* 368(6491):eabb6936.
10. Wölfel R, et al. (2020) Virological assessment of hospitalized patients with COVID-2019. *Nature* 581(7809):465–469.
11. Quicke K, et al. (2020) Longitudinal surveillance for SARS-CoV-2 RNA among asymptomatic staff in five Colorado skilled nursing facilities: Epidemiologic, virologic and sequence analysis. *medRxiv*. doi:10.1101/2020.06.08.20125989v1.
12. La Scola B, et al. (2020) Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. *Eur J Clin Microbiol Infect Dis* 39(6):1059–1061.
13. Liu Y, Rocklov J (2021) The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. *J Travel Med* 3(27):584–586.




273

274 **Figure S1.** Figure replicates Fig. 2 (main text) assuming only 50% adherence to group size limitations vs. the 90%
 275 adherence presented in the main text. **A.** Negative binomial R_E distribution with mean = 1.05 and dispersion
 276 parameter (k) = 0.10. The colored vertical dashes indicate group size limits that ‘chop the tail’ on the R_E
 277 distribution; for 90% of the population, coincident cases allocated to the same transmission event were truncated at
 278 the corresponding threshold for each intervention. **B.** Daily new cases and, **C.** Cumulative cases, across a 50-day
 279 time series with 95% confidence intervals by standard error depicted under corresponding, color-coded group size
 280 limits. Mean output of simulations under 50% adherence are shown as solid black lines, with the dashed line
 281 corresponding to mean output under the 90% adherence assumptions presented in the main text.
 282




284 **Figure S2.** Figure replicates Fig. 2 (main text) at a log-normal distribution for R_E , instead of negative binomial. **A.**
 285 Log-normal R_E distribution with a mean of 1.05 and a standard deviation of 1.233. The colored vertical dashes
 286 indicate the group size limits that ‘chop the tail’ on the R_E distribution. **B.** Daily new cases and, **C.** cumulative cases,
 287 across a 50-day time series under corresponding, color-coded group size limits.

288




289
 290 **Figure S3.** Figure replicates symptom-isolation panels from Fig. 3 (main text) in top row, showing **A.** mean
 291 reduction in R_E and **B.** cumulative cases saved across 50-day simulated epidemics under differing lag times to
 292 isolation, assuming a threshold titer for symptom onset by which ~32% of the population presents as asymptomatic.
 293 A comparison at a titer threshold for which ~51% of the population presents as asymptomatic demonstrates how a
 294 higher proportion of asymptomatic individuals in the population erodes the effectiveness of the symptom-based
 295 isolation intervention; asymptomatic status has no impact on the effectiveness of group size limits or asymptomatic
 296 surveillance testing interventions.



297
 298 **Figure S4.** Figure replicates symptom-isolation panels from Fig. 3 (main text) in top row, showing **A.** mean
 299 reduction in R_E and **B.** cumulative cases saved across 50-day simulated epidemics for NPIs of both symptom-based
 300 and testing-based isolation, across a range of different lag times or turnaround times to isolation (for, respectively
 301 symptom- or testing-based isolations). All testing-based interventions depicted are shown at a limit of detection= 10^1
 302 cp/ μ l. In the bottom row, **A.** mean reduction in R_E and **B.** cumulative cases saved are depicted for a comparative
 303 intervention which adds an additional single-day lag in contact tracing to the respective symptom-based or testing-
 304 based isolation. Under these combined interventions, even previously ineffective testing interventions with 10-day
 305 turnaround time show gains beyond no intervention at all.

306



307

308

309

310

311

312

313

314

315

316

317

318

319

320

321


322

323

324


Figure S5. Figure replicates Fig. 4 of the main text, under assumptions of 50% of cases lost to the outside community, as compared to the 10% modeled in the main article. **A.** Mean reduction in R_E , **B.** cumulative cases saved, and **C.** daily case counts for the first 50 days of the epidemic, across regimes of differing testing frequency and a combination of surveillance testing, contact tracing, symptomatic isolation, and group size limit interventions. All scenarios depicted here assumed test turnaround time, symptomatic isolation lags, and contact tracing lags drawn from a log-normal distribution with mean=one day. Limit of detection was fixed at 10^1 and group size limits at 12. Dynamics shown here are from simulations in which testing was limited to two test days per week. NPIs have proportionally less impact on R_E reduction (A) but nonetheless manage to avert an equal number of cases (B) when the university is modeled as a more open, community-integrated environment. Under this scenario, interventions function primarily to isolate cases from the external environment, rather than curb onward, within-community transmission. For this reason, daily variance in exposure rate is also diminished under assumptions of a higher proportion of transmissions lost to the surrounding community.

**Note: R_E reduction (panel A) is calculated as the difference in mean R_E in the absence vs. presence of a given NPI. The upper confidence limit (uci) in R_E reduction is calculated as the difference in uci R_E in the absence vs. presence of NPI. In our model, mean R_E in the absence of NPI equals 1.05 and uci R_E in the absence of NPI equals 8.6.*



325
 326 **Figure S6.** Figure extends results from Fig. 4 (main text), showing the standard deviation in cumulative cases from
 327 50-day simulated epidemics, across regimes of differing testing frequency and a combination of surveillance testing,
 328 contact tracing, symptomatic isolation, and group size limit interventions. All scenarios depicted here assume test
 329 turnaround time, symptomatic isolation lags, and contact tracing lags drawn from a log-normal distribution with
 330 mean=1 day. Limit of detection is fixed at 10^1 and group size limits at 12. Dynamics compare tests of differing
 331 frequency (semi-weekly, weekly, every two weeks) distributed across variable numbers of days in a given week
 332 (2,5,7). Additional layers of intervention and more testing days per week reduce the standard deviation in
 333 cumulative cases.

334
 335
 336
 337
 338
 339
 340
 341
 342



343


344 **Figure S7.** Figure largely replicates Fig. 4 of the main text, under assumptions of mean $R_0 = 6$ and 60% of the
 345 baseline campus population vaccinated, approximating circulation of the Delta variant in the undergraduate
 346 population of the University of Alabama, Tuscaloosa at the time of this writing. Note that y-axes for panel **A.** and **B.**
 347 differ from those depicted in Fig 4 of the main text and from Fig. S8 below. **A.** Mean reduction in R_E and **B.**
 348 cumulative cases saved compared to a baseline scenario in which no behavior-based or testing NPIs were applied
 349 but simulations were run under assumptions of 60% vaccination in an $R_0=6$ environment. **C.** Daily case counts for
 350 the first 50 days of the epidemic, across regimes of differing testing frequency and a combination of surveillance
 351 testing, contact tracing, symptomatic isolation, and group size limit interventions. All scenarios depicted here
 352 assumed test turnaround time, symptomatic isolation lags, and contact tracing lags drawn from a log-normal
 353 distribution with mean=one day. Limit of detection was fixed at 10^1 and group size limits at 12. Dynamics shown
 354 here are from simulations in which testing was limited to two test days per week. Combined, asymptomatic
 355 surveillance testing and behavior-based NPIs still reduce R_E and avert cases but impacts are reduced compared to no
 356 vaccination settings (main text) because fewer opportunities for infection arise. Variance between simulations and
 357 interventions is also diminished in this more mild epidemic scenario, indicating that testing alone, without rigorous
 358 extensive additional interventions, can effectively control outbreaks.

359 **Note: R_E reduction (panel A) is calculated as the difference in mean R_E in the absence vs. presence of a given NPI.*
 360 *The upper confidence limit (uci) in R_E reduction is calculated as the difference in uci R_E in the absence vs. presence*
 361 *of NPI. In our model, mean R_E under Delta variant transmission assumptions in the absence of NPIs, but including*
 362 *60% population-level vaccination, equals 1.12 and uci R_E equals 3.33.*

363

364

365



366

367 **Figure S8.** Figure largely replicates Fig. 4 of the main text, under assumptions of mean $R_0 = 6$ and 97.7% of the
 368 baseline campus population vaccinated, approximating circulation of the Delta variant in the undergraduate
 369 population of UC Berkeley at the time of this writing. Note that y-axes for panel **A.** and **B.** differ from those
 370 depicted in Fig 4 of the main text and from Fig. S7 above. **A.** Mean reduction in R_E and **B.** cumulative cases saved
 371 compared to a baseline scenario in which no behavior-based or testing NPIs were applied but simulations were run
 372 under assumptions of 97.7% vaccination in an $R_0=6$ environment. **C.** Daily case counts for the first 50 days of the
 373 epidemic, across regimes of differing testing frequency and a combination of surveillance testing, contact tracing,
 374 symptomatic isolation, and group size limit interventions. All scenarios depicted here assumed test turnaround time,
 375 symptomatic isolation lags, and contact tracing lags drawn from a log-normal distribution with mean=one day. Limit
 376 of detection was fixed at 10^1 and group size limits at 12. Dynamics shown here are from simulations in which testing
 377 was limited to two test days per week. Even in highly vaccinated university settings, behavior-based NPIs and
 378 asymptomatic surveillance testing reduce R_E and avert cases largely derived from breakthrough infections, though
 379 lower baseline case counts equate to lower gains in R_E reduction and case aversions. Variance between simulations
 380 and between interventions is most diminished in this epidemic scenario, indicating that testing alone, without
 381 rigorous extensive additional interventions, can effectively control outbreaks.

382 **Note: R_E reduction (panel A) is calculated as the difference in mean R_E in the absence vs. presence of a given NPI.*
 383 *The upper confidence limit (uci) in R_E reduction is calculated as the difference in uci R_E in the absence vs. presence*
 384 *of NPI. In our model, mean R_E under Delta variant transmission assumptions in the absence of NPIs, but including*
 385 *97.7% population-level vaccination, equals 0.17 and uci R_E equals 0.51.*

386
387

388
389

390
391

392
393

394 **Legends for Datasets S1-S3.**

395 **Dataset S1. Averaged total cases saved and mean R_E reduction across group size limit,**
396 **symptomatic isolation, and surveillance testing NPIs.** Summarized model output from 100x
397 simulations across all NPIs presented in Fig. 2 and Fig. 3, main text. Confidence intervals
398 represent 1.96*standard deviation in case reduction or R_E reduction.

399

400 **Dataset S2. Averaged total cases saved and mean R_E reduction across symptomatic**
401 **isolation, and surveillance testing NPIs, under regimes with and without contact tracing.**
402 Summarized model output from 100x simulations across all NPIs presented in SI-Appendix, Fig.
403 S3.

404

405 **Dataset S3. Averaged total cases saved and mean R_E reduction across combined**
406 **intervention approaches.** Summarized model output from 100x simulations across all NPIs
407 presented in Fig. 4, main text.

408

409 All other model output available as saved .Rdata files in our publicly-available Github
410 repository:

411 Brook CE, Northrup GR, Boots M (2020) Code for “Optimizing COVID-19 control with
412 asymptomatic surveillance testing in a university environment.” doi:10.5281/zenodo.4131223

413

414

415

416

417